Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
ProShares Pet Care ETF (PAWZ): Tracking the Pet Ownership Theme

ProShares Pet Care ETF (PAWZ): Tracking the Pet Ownership Theme

Key Takeaways

  • PAWZ tracks the FactSet Pet Care Index, a tier-weighted global basket of roughly 36 companies tied to pet ownership and pet-care spending.
  • The portfolio leans heavily toward animal-health and diagnostics names, with healthcare representing roughly 44% of assets, followed by consumer cyclical and consumer staples exposure.
  • Top holdings include Chewy, Zoetis, IDEXX Laboratories, Freshpet, and France-based Virbac.
  • The fund is passively managed, non-diversified, and carries a 0.50% expense ratio on a comparatively small asset base.
  • After a period of weakness near its 52-week low, the fund rebounded into the mid-$50s in recent weeks, a move led by its largest healthcare and consumer holdings.
  • For additional detail on this ticker's valuation and outlook, explore Price Targets and Forecast pages for deeper analytical context.
  • Investors can also explore automated strategies and market scans through Trending AI Robots for complementary research tools.

Overview of the ProShares Pet Care ETF (PAWZ)

The ProShares Pet Care ETF (PAWZ) is a passively managed exchange-traded fund that seeks to track the FactSet Pet Care Index. The underlying index measures the performance of companies positioned to benefit from interest in, or spending on, pet ownership. Under normal circumstances, the fund invests at least 80% of its total assets in index components or instruments with similar economic characteristics.

The portfolio is concentrated, holding roughly 36 securities, and is non-diversified. Its largest positions include online pet retailer Chewy, animal-health leaders Zoetis and IDEXX Laboratories, fresh-pet-food maker Freshpet, and France's Virbac, a veterinary pharmaceutical company. Additional notable names include pet insurer Trupanion, Merck, Oil-Dri, Colgate-Palmolive, and Petco. When screening for comparable holdings, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Sector allocation skews toward healthcare at roughly 44%, reflecting animal-pharmaceutical and diagnostic exposure, with consumer cyclical near 22% and consumer staples around 21%. By geography, the United States accounts for roughly 65% of assets, followed by the United Kingdom, France, Switzerland, and Canada. The fund charges a 0.50% expense ratio and maintains a relatively small asset base in the low tens of millions of dollars.

The Pet Care Industry Landscape

Pet care has evolved from a discretionary niche into a structurally resilient consumer category. Household pet ownership remains elevated, and spending on veterinary services, premium nutrition, and pet insurance has proven comparatively defensive during periods of economic uncertainty. This backdrop supports the long-term demand drivers behind the fund's animal-health, diagnostics, and specialty-retail holdings.

At the same time, the theme spans several distinct market segments with different dynamics. Animal-health and diagnostics companies, such as Zoetis and IDEXX Laboratories, are influenced by clinic visit volumes, biologic and pharmaceutical demand, and pricing power. Consumer-focused names like Chewy and Freshpet respond to e-commerce adoption, premiumization, and household budget sensitivity. The mixed healthcare and consumer profile means the ETF is exposed to both defensive, recurring-revenue businesses and more cyclical retail spending.

Macroeconomic conditions remain relevant. Inflation trends and interest-rate expectations shape valuation multiples across growth-oriented healthcare and consumer names, while foreign-exchange movements matter given the fund's roughly one-third non-U.S. weighting. Consolidation and innovation in animal health also continue to influence the competitive landscape.

Recent Performance and Positioning

PAWZ has been volatile over the trailing year, trading within a wide range from the high-$40s to the low-$60s. The fund weakened through much of the third quarter, with shares reaching the mid-$46 level in late September and early October, near the bottom of its 52-week range. That decline coincided with pressure on several large healthcare and consumer holdings and reflected broader risk-off conditions in the theme.

The most recent stretch has been markedly different. From the mid-$46 area in early October, the fund staged a sharp recovery into the mid-$55 range by mid-November, a rise of roughly 20% off its lows and a move of nearly 10% over the most recent 30-day window. The rebound was broad-based but concentrated in the portfolio's largest positions, with strength in animal-health and diagnostics names and renewed momentum in pet e-commerce and premium-nutrition holdings contributing most to the recovery. Sizable single-day gains in early November suggest a catalyst-driven, rather than purely gradual, advance. I reviewed the recent patterns using Tickeron’s AI Real Time Patterns to confirm the timing of the move.

Despite the rebound, the fund's relatively thin trading volume and modest asset base can amplify price swings and widen bid-ask spreads, a structural consideration for investors evaluating positioning and execution.

Factors to Watch Through 2026

Several structural factors are likely to shape PAWZ through 2026. In animal health, the earnings cycles of Zoetis, IDEXX Laboratories, and Virbac will remain central, with clinic utilization, biologic demand, and product innovation serving as key variables. For the consumer segment, e-commerce share gains at Chewy and Freshpet's capacity expansion and margin trajectory will influence the fund's retail-driven holdings.

The macroeconomic environment also matters. The path of interest rates and inflation will continue to affect valuation multiples for growth-oriented healthcare and consumer names, while foreign-exchange shifts could impact the non-U.S. portion of the portfolio. Household spending resilience will be a swing factor for discretionary pet purchases even as veterinary care retains its defensive characteristics.

Finally, thematic ETF competition and capital flows are worth watching. As a small, non-diversified fund, PAWZ's performance can be influenced by sector rotation into or out of defensive and consumer themes, and by the relative appeal of pet-care exposure versus broader healthcare and consumer strategies. Monitoring holdings-level fundamentals, regulatory developments in veterinary medicine, and institutional positioning will provide the most useful context for assessing the fund's trajectory.

Using Tickeron’s AI Tools for Research

In my own work, Tickeron’s AI Screener has become a practical way to scan for thematic ETFs and compare sector exposures quickly. The platform lets me apply technical indicators, fundamentals, and AI signals to surface patterns across similar holdings without manual effort. I find it especially useful when evaluating smaller funds like PAWZ against broader peers in healthcare and consumer categories.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PAWZ

PAWZ saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for PAWZ moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 65 similar instances where the indicator exited the overbought zone. In 57 of the 65 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PAWZ moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 17 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.

The Moving Average Convergence Divergence Histogram (MACD) for PAWZ turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAWZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

PAWZ broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

PAWZ moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PAWZ crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.

Following a +5.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAWZ advanced for three days, in 227 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 158 of 229 cases where PAWZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Colgate-Palmolive Company (NYSE:CL), ZOETIS (NYSE:ZTS), General Mills (NYSE:GIS), Tractor Supply Co (NASDAQ:TSCO), Elanco Animal Health (NYSE:ELAN), Chewy (NYSE:CHWY).

Industry description

The investment seeks investment results, before fees and expenses, that track the performance of the FactSet Pet Care Index (the "index"). The fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the index. The index is designed to measure the performance of companies that stand to benefit from interest in or resources spent on pet ownership. Under normal circumstances, it will invest at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Pet Care ETF (PAWZ) ETF is 41.62B. The market cap for tickers in the group ranges from 847.8M to 362.01B. MRK holds the highest valuation in this group at 362.01B. The lowest valued company is WOOF at 847.8M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Pet Care ETF (PAWZ) ETF was 7%. For the same ETF, the average monthly price growth was 34%, and the average quarterly price growth was 16%. TRUP experienced the highest price growth at 7%, while CHWY experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the ProShares Pet Care ETF (PAWZ) ETF was 9%. For the same stocks of the ETF, the average monthly volume growth was -15% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 70
P/E Growth Rating: 56
Price Growth Rating: 41
SMR Rating: 58
Profit Risk Rating: 78
Seasonality Score: 25 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.